Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Genmab announced Phase 2 results for Rina-S (rinatabart sesutecan) in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months and median progression-free survival of 9.5 months. The drug showed antitumor activity regardless of folate receptor alpha expression levels, with manageable tolerability. The company is advancing four Phase 3 trials across multiple gynecologic cancers.